SEC Filing Summary
Company and period: The source filing identifies CryoLife, Inc. (not Artivion, Inc.) as the registrant. This unaudited Form 10-Q covers the quarter ended March 31, 2017; comparisons are with the quarter ended March 31, 2016 unless noted. Dollar amounts below are in millions except per-share data.
Financial performance
| Metric | Q1 2017 | Q1 2016 | Change / context |
|---|---|---|---|
| Revenue | $45.1 | $43.0 | Up 5%; driven by On-X and preservation services |
| Product revenue | $27.4 | $27.0 | Up 1%; On-X growth partly offset by divested product lines |
| Preservation services revenue | $17.7 | $16.0 | Up 10% |
| Gross profit / margin | $29.5 / 65% | $27.6 / 64% | Gross profit up 7% |
| Operating income | $2.5 | $6.7 | Lower mainly because the prior-year period included an $8.8 gain on the HeRO sale, partly offset by an $0.8 ProCol sale loss |
| Net income | $2.2 | $2.5 | Diluted EPS was $0.06 vs. $0.08 |
| Operating cash flow | $3.9 | $1.4 | Improved year over year |
Product detail: On-X revenue rose 32% on the reported product-line comparison to $8.9 million; management also cited a 12% increase against On-X’s combined pre- and post-acquisition year-ago revenue. BioGlue and BioFoam revenue increased 2% to $15.7 million. CardioGenesis fell 20% to $1.6 million, and PerClot fell 17% to $0.8 million. Vascular preservation revenue reached a quarterly record of $10.2 million.
Balance sheet and liquidity
- Cash and cash equivalents were $58.9 million at March 31, 2017, up from $56.6 million at year-end; restricted securities were $0.7 million.
- Current assets were $149.2 million and current liabilities $28.1 million, yielding $121.1 million of working capital and a reported current ratio of approximately 5:1.
- Term-loan principal was $73.1 million; the balance-sheet carrying amount, net of unamortized issuance costs, was $71.2 million. The $20.0 million revolving facility was undrawn and fully available. The term loan matures January 2021; its aggregate interest rate was approximately 3.73% at quarter-end. The company reported compliance with its debt covenants.
- Cash increased by $2.2 million during the quarter. Investing used $1.2 million, including $2.0 million in capital expenditures and $0.7 million of proceeds from the HeRO sale; financing used $0.5 million, including $0.5 million of term-loan repayment.
Material changes, outlook, and notable items
- Operating expenses were $27.0 million, down from $28.9 million. General, administrative, and marketing expense fell 13%, partly because Q1 2016 included $5.6 million of On-X transaction and integration costs. Research and development expense rose 57% to $4.1 million, primarily for PerClot, NeoPatch, On-X, and BioGlue programs.
- Q1 2017 product cost included $2.0 million of inventory basis step-up expense, primarily for On-X inventory repurchased from distributors, compared with $0.6 million in Q1 2016. Preservation-services cost decreased 10% as per-unit tissue processing costs declined.
- The effective tax rate was a 27% benefit in Q1 2017, including approximately $1.1 million of excess tax benefits from stock awards; Q1 2016 had a 58% tax expense. The tax benefit helped offset lower pretax income.
- Management expected full-year 2017 On-X product revenue to increase versus 2016, while On-X OEM revenue and CardioGenesis revenue were expected to decrease. It expected lower per-unit tissue-processing costs for full-year 2017. These are expectations, not quantified revenue or earnings guidance.
- Management stated cash and operating cash flows were expected to meet operational liquidity needs for at least 12 months. Future cash needs include debt service, clinical trials, R&D, working capital, capital spending, and potentially business development; additional financing might be needed for significant business development.
- On-X’s European CE Mark suspension for its ascending aortic prosthesis remained in effect pending review of further information; the company warned that failure to lift it could materially affect 2017 EEA revenue.
- PerClot’s U.S. pivotal-trial enrollment resumed in Q4 2016; management said FDA approval could occur in 2019 if enrollment proceeded as anticipated. A settlement-related restriction prevents U.S. marketing, sale, or distribution before February 8, 2019, even if approval comes sooner. Failure to obtain approval could impair related assets, including $1.5 million of prepaid royalties, $2.8 million of net intangibles, and $1.2 million of net property and equipment.
- The company was pursuing recovery of approximately $10 million held in escrow from the On-X acquisition and asserted indemnification claims; the former shareholders’ representative objected. Negotiation or litigation outcomes were uncertain, and recovery was not assured.
- Key risks include dependence on BioGlue and tissue-preservation revenue, tissue supply and processing variability, competition and foreign-exchange exposure, regulatory and product-quality risks, integration and leverage risks, and clinical-trial and reimbursement uncertainty. Management noted seasonal demand patterns for certain products and services.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing names CryoLife, Inc., despite the request metadata naming Artivion, Inc.
- Track On-X valve growth, OEM customer activity, and resolution of the European CE Mark suspension.
- Monitor tissue-service revenue and processing costs, which can vary with tissue supply, yields, timing, and demand.
- Check PerClot trial enrollment, the projected approval timeline, the contractual October 2017 milestone provision, and the U.S. marketing restriction through February 2019.
- Follow the On-X escrow dispute, debt repayment and covenant headroom, and the sustainability of cash generation and the Q1 tax benefit.